Print this page
-
Needs Survey for Childhood, Adolescent, Young Adults (CAYA) Cancer Survivors, Their Siblings, and Parents/Caregivers.
Protocol: 132213Principal Investigator:
- Katie Devine (Rutgers University)
Applicable Disease Sites: Leukemia, not otherwise specified
Brain and Nervous System
Any Site
Non-Hodgkin's Lymphoma
Leukemia, other
Hodgkin's Lymphoma
Bones and Joints -
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients.
Protocol: 111708Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Brain and Nervous System -
A Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma.
Protocol: 111914Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Brain and Nervous System -
A Phase 3 Study of Selumetinib or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations.
Protocol: 112102Principal Investigator:
- Richard Drachtman M.D. (Rutgers University)
Applicable Disease Sites: Brain and Nervous System -
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor.
Protocol: 112104Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Brain and Nervous System -
Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma.
Protocol: 142202Principal Investigator:
- Vincent Yeung (Rutgers Cancer Institute of New Jersey-University Hospital)
Applicable Disease Sites: Brain and Nervous System
- 1
- 2